Salivary duct carcinoma, a rare highly aggressive epithelial malignancy, commonly presents at advanced stage in elderly patients of both sexes [1–3]. The primary management of SDCs is surgery and/or post-operative radio-therapy while advanced primary and metastatic disease are empirically treated with either conventional chemo-radiotherapy or targeted agents with limited success [4,5]. SDC, like mammary ductal carcinoma, manifest high expression of HER-2 and Androgen Receptor (AR) and frequent alterations of the PI3K signaling pathway [6–13].
http://ift.tt/2rb5T2K
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου